



Caribou Biosciences to Participate in Upcoming Investor Conferences

November 3, 2025

BERKELEY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the following investor conferences:

- **2025 Truist Securities BioPharma Symposium**, New York
November 6, 2025
- **8th Annual Evercore Healthcare Conference**, Coral Gables, FL
December 2, 2025 with fireside chat at 8:45-9:05 AM ET
[Webcast](#)

For more information and links to webcasts, please visit the [Events](#) page on Caribou's website. Webcasts will be available on the Caribou website for at least 30 days after the event.

About Caribou Biosciences, Inc.

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The Company's genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies.

Caribou Biosciences, Inc. contact:

Peggy Vorwald, PhD
media@cariboubio.com
investor.relations@cariboubio.com